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life-year (QALY) gain among T2DM patients treated with dapa vs. other antidiabetic 
drugs. Changes in clinical endpoints, including HbA1c, weight, systolic blood pressure 
(SBP), and hypoglycemia risk, associated with 52-week treatment with the different 
antidiabetic drugs were obtained from a network meta-analysis. Annual medical 
costs and QALYs for changes in clinical endpoints were obtained from published 
literature. RESULTS: For one year of treatment of a T2DM patient, medical costs 
associated with changes in HbA1c, weight, SBP, and hypoglycemia risk for dapa were 
-$173 (Confidence interval: -$1,125, $747) vs. GLP-1 agonists, -$1,061 (-$1,859, -$362) 
vs. DPP-4 inhibitors, -$1,524 (-$2,552, -$649) vs. TZDs, and -$2,300 (-$3,131, -$1,574) 
vs. SUs. Results from univariate and multivariable sensitivity analyses showed that 
the estimates of the medical cost differences were most affected by variations in 
weight and SBP changes, but were generally robust when model parameters were 
varied. Treatment with dapa was cost saving vs. other antidiabetic drugs when only 
medical costs were considered. When drug costs were included, treatment with dapa 
remained either cost saving (vs. GLP-1 agonists and DPP-4 inhibitors) or cost-effective 
vs. TZDs ($10,007 per QALY), vs. SUs ($9,650 per QALY). CONCLUSIONS: Treatment of 
T2DM patients with dapa was associated with reduced medical costs vs. daily dosage 
GLP-1 agonists, DPP-4 inhibitors, TZDs, and SUs. When drug costs were included, treat-
ment with dapa was cost saving vs. daily dosage GLP-1 agonists and DPP-4 inhibitors 
and cost-effective vs. TZDs and SUs.
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OBJECTIVES: To compute the cost of medicines used in the treatment of T2DM and 
study the variation in the costs. METHODS: Indian Council of Medical Research 
(ICMR) and International Diabetes Federation (IDF) guidelines were used to under-
stand the treatment of T2DM. Current Index of Medical Specialities (CIMS) Apr-
July2014 issue and Indian Drug Review (IDR) issue 2, Feb2014 were used to capture 
the prices of medicines available in the Indian market. The annual cost of treatment 
and variation in the annual cost of drugs was studied. RESULTS: IDF recommends 
first line treatment with metformin 500mg twice a day. The annual cost of treat-
ment with metformin was found to be Rs.467-2336. A variation of 400% is noted 
in the least-highest cost of metformin. Glimepiride 2mg OD is used as a second 
line treatment and its annual cost ranges between Rs.458-4851. It shows maxi-
mum variation of 960% in the least-highest cost. Likewise, third line treatment can 
be started either with α -Glucosidase inhibitor or DPP4 inhibitor or Thiazolidine 
group of drugs. Annual cost of treatment with Pioglitazone 15mg was found to 
be Rs.365-2555. Among the third line category of drugs, Pioglitazone 15mg shows 
maximum variation of 600% in the least-highest cost. Used as a fixed dose combina-
tion (FDC), Glimepiride+Metformin (1+500 mg) showed maximum price variation of 
529%. CONCLUSIONS: It was concluded that a maximum of 11 fold variation was 
observed in the least-highest costs of treatment with Glimepiride 2mg in the year 
2014. Wide variation exists in the percentage price variation of same drug manu-
factured across the different brands.
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OBJECTIVES: To assess economic burden and quality of life (QoL) associated with 
acromegaly in the United States. METHODS: A web-based cross-sectional sur-
vey was conducted from August –October, 2014. Patient-reported information on 
acromegaly-related economic burden was collected. The direct and indirect costs 
per patient over the past 3 months included out-of-pocket cost, sick leave, leave of 
absence, direct loss of job due to acromegaly, unemployment, assistance to perform 
household chores, and family member loss of income. The QoL was assessed by 
Acromegaly Quality of Life (AcroQoL) and EQ-5D questionnaires. Descriptive analysis 
was used. RESULTS: A total of 106 patients completed the survey (mean age: 46 
years, female: 76%). The annualized office visits per person to physicians, nurses 
and other health professionals was 11.8, 3.4 and 6.6 visits, respectively. The acro-
megaly patients had 0.7 emergency room visits, 0.3 hospital admissions and length 
of hospital stay of 1.8 days. Annualized healthcare out-of pocket cost was $1,790/
person. The average number of days unable to work was 34 days with estimated 
income loss $6,702 /person-year. The average annual loss of income due to direct 
loss of job, unemployment disability, household chores, and income loss of family 
members was $6,106, $10,653, $1,685, and $472/person, respectively. As compared 
with low-symptom group, symptom 0-3 (n= 41), the high-symptom group with 4+ 
symptoms (n= 65) had significantly higher costs by category (loss of job: $8,876 
vs. $1,717, p= 0.017; unemployment disability: $17,102 vs. $429, p= 0.003; house-
hold chores: $540 vs. $233, p= 0.0003; family members’ loss: $128 vs. $23, p= 0.028). 
The average EQ-5D index score and global score of AcroQoL were 0.62±0.23 and 
38.61±22.39, respectively. Patients reporting 4 + symptoms had lower QoL scores as 
compared with those with fewer symptoms (EQ-5D: 0.53 vs. 0.75, p< 0.0001; AcroQoL: 
27.38 vs. 56.43, p< 0.0001). CONCLUSIONS: Patients with acromegaly experienced 
high economic burden and poor quality of life.
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OBJECTIVES: Type 2 diabetes mellitus (T2DM) is a prevalent disease affecting over 
25 million people in the United States. Diabetes inflicts a heavy economic burden 
costs ($347) due to longer lifetimes, and had a direct medical cost reduction (-$1,716) 
due to improved glycemic control. CONCLUSIONS: The AUTONOMY Q1D titration 
algorithm offers a simple and effective approach to assist patients requiring basal-
bolus therapy in adjusting their meal-time insulin dose. Results from our study 
indicate that compared to published delays in treatment modification or escalation, 
an adaptive daily titration algorithm can lead to better outcomes at lower costs.
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OBJECTIVES: The IDF global guideline for type-2 DM considers metformin as first-
line therapy, without contraindications, but gastrointestinal intolerance occurs in 
20-30% of patients receiving an immediate release of metformin, being a possible 
barrier to treatment adherence. Glucophage® XR is an extended-release formulation 
of metformin IR, with the same antidiabetic efficacy, a flexible dosing range to assist in 
treatment titration with superior gastrointestinal tolerability, contributing to greater 
compliance. The aim of this study is to evaluate the cost-effectiveness (CE) and budget 
impact (BI) of metformin XR compared to metformin IR, in adults with type-2 DM, 
from the perspective of the public health system in Brazil. METHODS: The outcomes 
of interest were days on treatment; number of events (stroke, myocardial infarc-
tion, heart failure, peripheral mononeuropathy, retinopathy, blindness, diabetic foot, 
amputation, diabetic nephropathy and renal disease); number of full-lifetime-patients 
without treatment (non-compliance); number of full-lifetime-patients with controlled 
diabetes; and life years. Efficacy data were obtained from literature review and unit 
costs were obtained from official price lists. The time horizon of the CE and BI model 
was 30 and 10 years respectively. A 5% annual discount rate was applied to costs and 
benefits in the CE model. RESULTS: Glucophage® XR increased overall survival in 0.75 
day and assured more 1,631 days on treatment, per patient, during lifetime period. 
Also, reduced 6,249 events and allowed more 143 full-lifetime-patients with controlled 
type-2 DM, per 1,000 patients. Glucophage® XR was dominant vs. Metformin IR, result-
ing in saving approximately 5.5% (BRL 10,961,011 per patient). Additionally, the use 
of Glucophage® XR in patients with type-2 DM resulted in saving of approximately 
BRL 3,787,758,740.88 in the period from 2014 to 2025. CONCLUSIONS: Glucophage® 
XR showed dominance versus metformin IR due to a safer profile leading to better 
tolerance, compliance and better health outcomes.
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OBJECTIVES: To estimate and compare annual direct medical costs associated 
with diabetic complications in patient with type 2 diabetes in the USA and South 
Korea. METHODS: Data were obtained from the 2010-2011 Medical Expenditure 
Panel Survey (MEPS), which is a nationally representative sample of ambulatory 
population in the US, and the 2010-2011 Korea Health Panel (KHP) which contains 
health service use and expenditures for a representative sample of Korea. Using 
ICD-9 CM codes, patients were classified as patients with microvascular complica-
tions only (nephropahty, neuropathy, retinopahty, or peripheral vascular disease), 
macrovascular complications only (cardiovascular disease and cerebrovascular 
disease), both complications, and without complications. Direct medical costs 
included costs associated with hospitalization, outpatient visits, emergency room 
visits, and drugs. To compare costs of diabetic patients with and without complica-
tions, direct medical costs were estimated using the generalized linear model (GLM) 
with log link function and gamma distribution after adjusting for patient charac-
teristics. RESULTS: Among 3,864 and 2,060 patients with diabetes in the US and 
Korea, respectively, 87.0% and 61.9% patients had no complications; 4.5% and 17.7% 
patients had microvascular complications only; 8.3% and 13.6% had macrovascular 
complications only; and 0.2% and 6.8% had both complications. The average annual 
direct medical costs per patient were $8,191 in the US and $1,590(US$1= KRW1,000) 
in Korea. After adjusting for patients’ characteristics, annual direct medical costs 
associated with microvascular complications were 2.36(US) and 2.05(Korea) times 
greater; macrovascular complications were 2.70(US) and 1.76 times(Korea) greater, 
while both complications were 5.66(US) vs. 3.08(Korea) times greater than those 
without complications, respectively. CONCLUSIONS: Direct medical treatment costs 
in patients with diabetic microvascular or macrovascular complications were sig-
nificantly higher than those without diabetes complications, and the magnitudes 
of additional costs are different between US and Korea. Providing proper treatment 
of diabetes to prevent or delay diabetic complications is important to minimize 
treatment costs of diabetes.
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OBJECTIVES: The objective of this study was to evaluate the short-term economic 
impact of treatment of type 2 diabetes (T2DM) patients with dapagliflozin (dapa) 
vs. other antidiabetic drugs, including daily dosage glucagon-like peptide-1 (GLP-1) 
agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), and 
sulfonylureas (SUs). METHODS: An economic model (1-year time horizon) was devel-
oped to evaluate differences in annual medical costs and costs per quality-adjusted 
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OBJECTIVES: To estimate the health and economic value of participation in digital 
lifestyle intervention program for people with prediabetes METHODS: The study 
investigated ‘Prevent’ program which is modeled after CDC’s Diabetes Prevention 
Program. The core phase of this digital program consisted of 16 weekly lessons, fol-
lowed by periodic follow-up to reinforce lesson content and provide encouragement. 
The analysis sample included 2,371 Prevent participants who were overweight or 
obese and have prediabetes. Participants’ weight at or before 26 weeks was stud-
ied to calculate weight change. A Markov-based microsimulation model simulated 
onset of obesity and diabetes comorbidities annually over 10 years among partici-
pants under two scenarios (1) weight loss and A1c improvements achieved through 
Prevent, and (2) natural history of disease in the absence of Prevent. A second popu-
lation that met USPSTF’s recommendation for intensive behavioral counselling was 
also evaluated following the same process to estimate the benefits of ‘Prevent’ in 
different populations. RESULTS: Participants with prediabetes experienced aver-
age weight loss of 5.13%. Prevent was associated with a 28% reduction in diabetes 
onset over 3 years and 30% over 5 years. Cumulative over 3 and 5 years, the present 
value of reduced medical expenditures averaged $1,310 and $2,870, respectively. 
Comparing medical savings to program costs, the break-even point was two years. 
The simulated return on investment (ROI) was $860 after 3 years, $2,420 after 5 
years, and $8,770 after 10 years. In the USPSTF population, the model projected 
reduction in disease onset similar to that in the prediabetes population. The ROI 
was $950, $2,370 and $7,500, for 3, 5, and 10 years, respectively. CONCLUSIONS: 
Intensive lifestyle intervention is recommended by the U.S. Preventive Services 
Task Force as the first-line treatment for prediabetes, and internet-based programs 
like Prevent appear to provide both substantial health benefits to participants and 
high return on investment.
PDB46
a hEalth EConoMiC Evaluation of thE EDgE stuDy using thE iMs CorE 
DiaBEtEs MoDEl
McEwan P.1, Evans M.2, Foos V.3, Paldánius P.M.4
1Health Economics and Outcomes Research Ltd, Monmouth, UK, 2University Hospital Llandough, 
Cardiff, UK, 3IMS Health, Basel, Switzerland, 4Novartis Pharma AG, Basel, Switzerland
OBJECTIVES: The observational, non-interventional EDGE study showed that vilda-
gliptin is effective in patients with type 2 diabetes mellitus who have suboptimal 
glycemic control on metformin (MET) monotherapy in the real-world setting, con-
firming the results of previous randomized clinical trials (RCTs). Cost-effectiveness 
evaluations are typically based on RCT data, which offer high internal validity and 
are the gold standard in evaluating efficacy and short-term safety. Nevertheless, 
they lack external validity and generalizability and there is a growing trend towards 
the complementary use of real-world data. Consequently, we sought to perform a 
health economic evaluation of the EDGE study using an established diabetes out-
comes model. METHODS: The IMS Core Diabetes Model (CDM), a recently validated 
diabetes model, was used to evaluate the costs and outcomes of MET+vildagliptin 
(M+V) compared to MET+sulfonylurea (M+S), based on data derived from the EDGE 
study worldwide. M+V was associated with HbA1c and BMI changes of -1.19% and 
0.199 kg/m2, respectively. Corresponding data for M+S were -0.99% and 0.707 kg/m2, 
respectively. Published network meta-analysis data were used to populate the CDM 
with hypoglycemia rates. The model was run over a lifetime, with costs ($US) and 
benefits discounted at 3.0%. RESULTS: Predicted quality-adjusted life expectancy 
(QALE) was 11.14 and 11.07 in patients treated with M+V and M+S, respectively. 
Total direct costs were estimated at $US 90,788 and $US 85,692 for patients treated 
with M+V and M+S, respectively. Incremental differences between M+V and M+S 
were 0.07 for QALE and $US 5,096 for total costs, yielding an incremental cost-
effectiveness ratio (ICER) of $US 72,800. CONCLUSIONS: In the real-world setting, 
compared to sulfonylureas, vildagliptin was estimated to be cost effective using US 
ICER thresholds. These data further highlight the potential role of real-world data 
in assessing health economic value.
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OBJECTIVES: Diabetes mellitus (DM) is a chronic disease considered a worldwide 
public health problem. DM can result in harm to the patient in the aspects clinical, 
social, economic and quality of life, given its potential of morbidity and mortality 
DM (SBD, 2003). Expenditures for financing costly dispensing drugs have shown 
continuous growth trend in the Brazilian National Health Service (SUS). This creates 
the need for rationalization and optimization of growing financial contributions of 
resources for health. The purpose of this study was to evaluate the cost-effective-
ness of Glargine - insulin analogue versus NPH - insulin in the treatment of diabetes 
mellitus type I and II. METHODS: We developed a decision model using Markov 
method to perform the cost-effectiveness of Glargine and NPH in the treatment 
of diabetes mellitus type I and II. Calculations were performed for a time horizon 
of 10 to 20 years in annual cycles. The perspective is that of the SUS. Additionally 
analysis Cost-utility and sensitivity were performed. RESULTS: In 20 years (with 5% 
discount), the effectiveness was equal (as in 10 years) between Glargine and NPH 
insulin presenting 7.62 Avg. The total cost to NPH insulin was U$9,114.95 and the 
total cost of insulin Glargine was U$21,128.49 In 20 years (with 5% discount), the 
utility was similar (as in 10 years) between Glargine and NPH insulin presenting 
on US health-care, both directly and through substantially increased risks of micro- 
and macrovascular complications over time. The goal of this study was to estimate 
diabetes-related clinical and economic outcomes following a myocardial infarction 
(MI) or stroke. The impacts of experiencing an MI or stroke on five-year mortal-
ity rates and life expectancy were estimated using National Health and Nutrition 
Examination Survey data. METHODS: A Monte Carlo microsimulation was devel-
oped to estimate the number of complications, mortality, and diabetes-related medi-
cal costs for T2DM patients. The simulation uses T2DM comorbidities from the CDC 
diabetes cost-effectiveness group and risk equations from the United Kingdom 
Prospective Diabetes Study (UKPDS 82). Five-year mortality rate and medical and 
pharmacy costs were estimated for a cohort of 100,000 patients. Cohorts were simu-
lated for five years and projected over a lifetime with and without an initial MI or 
stroke event for both genders and different age groups. One-way sensitivity analyses 
including years since diagnosis, baseline HbA1c, blood pressure, cholesterol, and 
smoking were performed separately for MI and stroke. RESULTS: A 60-year-old male 
patient with a 7.5% baseline HbA1c was estimated to have a mortality rate of 0.15 
over five years and to incur $22,096 without an initial MI or stroke. The mortality and 
cost increased to 0.44 and $69,286 after an initial MI and 0.51 and $73,297 after an 
initial stroke. The patient’s life expectancy decreased from 14.8 years to 7.9 and 6.6 
years after an initial MI and stroke, respectively. CONCLUSIONS: Diabetes-related 
vascular complications significantly decrease life expectancy and increase the eco-
nomic burden of T2DM. Preemptive actions and treatments to reduce MI and stroke 
risk in T2DM patients can be cost-justified.
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OBJECTIVES: The use of ultrasonic devices (UD) in thyroidectomy may have sig-
nificant economic impact due to improved efficiency and benefits of clinical out-
comes without increasing rates of surgical complications. To fully characterize the 
potential economic benefit of UD in thyroidectomy, the objective of this study was 
to develop a provider budget impact model to quantify potential cost savings over 
conventional surgical techniques. METHODS: A budget impact model was devel-
oped in the perspective of a US hospital, comparing the use of UD with conventional 
techniques in patients undergoing thyroidectomy. Clinical parameters were derived 
from published literature, including a meta-analysis of 26 studies, and focused on 
the differences between ultrasonic and conventional surgeries across four areas: 1) 
operating time, 2) blood loss, 3) duration of recovery time, and 4) risks of other com-
plications. Costs of care were obtained from published commercial and Medicare 
fee schedules, and other costs and risks relating to thyroidectomy were obtained 
from published literature. RESULTS: UD showed clinical and economic advantages 
compared to conventional surgery, with notable reductions of operating time and 
blood loss by 29% and 20%, respectively. Reductions were also seen in risk of surgi-
cal site infection and anesthesia utilization due to reduction in operating time, 
with the possibility of reducing other surgical side effects associated with operat-
ing time such as venous thromboembolism. Total cost savings were estimated at 
approximately $1,501 per patient, with the higher up-front cost of the UD offset 
by the aforementioned savings. CONCLUSIONS: The clinical benefits of UD can 
be translated into economic benefits for providers in the US. Further studies are 
needed to assess the impact of those benefits on clinical practice, especially tak-
ing into account the practical consequences of reduced operating time, including 
potential shift in setting from inpatient to outpatient care and possible increases 
in the rate of procedures performed.
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OBJECTIVES: To evaluate health care resource utilization and costs among diabetes 
patients residing in long-term care facilities. METHODS: Patients diagnosed with 
diabetes (International Classification of Diseases, 9th Revision, Clinical Modification 
diagnosis codes 250.x0, 250.x2) were identified using the Long-Term Care Minimum 
Data Set (MDS) linked to 5% Medicare data from 01JAN2009 through 31DEC2010. The 
initial diagnosis date was designated as the index date. A comparison cohort was 
created for patients without diabetes, using 1:1 propensity score matching (PSM) 
to control for age, region, gender and baseline Charlson Comorbidity Index score. 
The index date for the comparison cohort was randomly chosen to reduce selec-
tion bias. Patients in both cohorts were required to be age ≥ 65 years, have at least 
two consecutive quarterly assessments documented in MDS data 6 months prior 
to the index date and have continuous medical and pharmacy benefits for 1-year 
pre- and post-index date. Health care resource utilization and costs were compared 
between the diabetes and comparison cohorts. RESULTS: After applying PSM, 783 
patients were included in each cohort, and baseline characteristics were balanced. 
Diabetes patients had a higher percentage of inpatient (31.29% vs. 22.73%, p= 0.0001), 
skilled nursing facility (SNF, 31.55% vs. 22.73%, p< 0.001), durable medical equip-
ment (27.46% vs. 16.48%, p< 0.0001) and pharmacy visit claims (93.10% vs. 88.76%, 
p= 0.0028) compared to those without diabetes. Patients in the diabetes cohort also 
incurred significantly higher inpatient ($5,801 vs. $3,071, p< 0.0001), SNF ($5,532 vs. 
$3,244, p< 0.0001), carrier claim ($3,118 vs. $2,437, p= 0.0002) and pharmacy visit costs 
($5,040 vs. $4,275, p= 0.0005) than those in the comparison cohort. CONCLUSIONS: 
Patients diagnosed with diabetes had significantly higher health care resource uti-
lization and costs than those without diabetes.
